The Immune System's Dual Role
In a healthy gut, the immune system performs a remarkable balancing act: it mounts vigorous responses against pathogens while tolerating the trillions of commensal bacteria that inhabit the colon. In inflammatory bowel disease, this balance breaks down — the immune system attacks the intestinal tissue as if it were a threat, producing chronic inflammation that damages the gut wall.
Innate Immunity: The First Responder
The innate immune system provides immediate, non-specific defence. In IBD, innate immune dysfunction includes: defective antimicrobial peptide production by Paneth cells (particularly α-defensins in Crohn's disease, associated with NOD2 gene mutations), impaired autophagy (the cellular recycling process that clears intracellular bacteria — variants in ATG16L1 and IRGM genes increase Crohn's risk), dysregulated macrophage and neutrophil activation (producing excessive TNF-α, IL-1β, and IL-6), and increased intestinal permeability allowing bacterial antigen translocation into the lamina propria.
Adaptive Immunity: The Sustained Attack
Adaptive immunity provides specific, memory-driven responses. In Crohn's disease, the immune response is characterised by Th1 and Th17 dominance — producing IFN-γ, IL-17, and IL-22 that drive granulomatous, transmural inflammation. In ulcerative colitis, a Th2-skewed response predominates — with IL-5 and IL-13 driving mucosal inflammation and disrupting epithelial barrier function. Both conditions show defective regulatory T cell function — meaning the brakes on inflammation are insufficient.
Loss of Tolerance
The fundamental defect in IBD is loss of immune tolerance to commensal gut bacteria. Normally, dendritic cells in the gut sample bacterial antigens and present them to T cells in a tolerogenic context — promoting Treg differentiation and IL-10 production. In IBD, this process fails: dendritic cells present bacterial antigens in an inflammatory context, activating effector T cells that drive chronic inflammation. The result is an immune system that treats its own normal flora as an invasion.
Why Immunosuppression Works
IBD medications target specific components of this immune cascade. Anti-TNF agents (infliximab, adalimumab) neutralise the pro-inflammatory cytokine TNF-α, a central mediator of innate immune activation. Anti-IL-12/23 agents (ustekinumab) and anti-IL-23 agents (risankizumab) target the Th1/Th17 pathways. Anti-integrins (vedolizumab) block lymphocyte trafficking to the gut. JAK inhibitors (tofacitinib, upadacitinib) interfere with intracellular cytokine signalling across multiple pathways. Each agent intervenes at a different point in the immune cascade — which is why different patients respond to different drugs.
What This Means for Patients
Understanding that IBD is fundamentally an immune-mediated disease — not caused by diet, stress, or personal weakness — frames treatment rationally. Immunosuppressive medications reduce the immune system's inappropriate attack on intestinal tissue. They do not weaken you indiscriminately — targeted biologics are designed to modulate specific immune pathways while preserving general immune competence. Infection risk is modestly increased but manageable with appropriate monitoring and vaccination.